Literature DB >> 1717069

Dynamics of leukocyte-platelet adhesion in whole blood.

H M Rinder1, J L Bonan, C S Rinder, K A Ault, B R Smith.   

Abstract

The dynamics of leukocyte-platelet adhesion and platelet-platelet interaction in whole blood are not well understood. Using different platelet agonists, we have studied the whole blood kinetics of these heterotypic and homotypic interactions, the relative abilities of different leukocyte subsets to participate in platelet adhesion, and the ligands responsible for adhesion. When platelet aggregation was inhibited by the Arg-Gly-Asp-Ser (RGDS) peptide, thrombin stimulation of whole blood resulted in platelet expression of granule membrane protein 140 (GMP-140) and, simultaneously, a marked increase in the percentage of monocytes and neutrophils (PMN) binding platelets, as well as an increase in the number of platelets bound per monocyte and PMN. Lymphocytes were unaffected. Monocytes bound more platelets and at an initially faster rate than PMN. This increase in monocyte and PMN adhesion to platelets was completely inhibited by the blocking monoclonal antibody (MoAb), G1, to GMP-140. When the combination of epinephrine and adenosine diphosphate (epi/ADP) was used as a less potent agonist in the presence of RGDS, GMP-140 expression per platelet was less, and while monocyte-platelet conjugates formed, PMN-platelet conjugates did not. With epi/ADP in the absence of RGDS, there was an immediate, marked decrease in the percentage of all leukocytes with bound platelets, simultaneous with an increase in the percentage of unbound platelet aggregates. As these platelet aggregates dissociated, the percentage of monocytes and PMN with adherent platelets increased, with monocytes again binding at a faster initial rate than PMN. This recovery of monocyte and PMN adhesion to platelets was also inhibited by the G1 MoAb. We conclude that: (1) monocytes and PMN bind activated platelets in whole blood through GMP-140; (2) monocytes have a competitive advantage over PMN in binding activated platelets, particularly when less potent platelet agonists are used; and (3) platelet aggregate formation initially competes unactivated platelets off leukocytes; subsequent aggregate dissociation allows the now activated platelets to readhere to monocytes and PMN through GMP-140. These studies further elucidate the dynamic interaction of blood cells and possible links between coagulative and inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717069

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Platelet activation In mice and human Helicobacter pylori infection.

Authors:  J I Elizalde; J Gómez; J Panés; M Lozano; M Casadevall; J Ramírez; P Pizcueta; F Marco; F D Rojas; D N Granger; J M Piqué
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Inflammation and atherosclerosis.

Authors:  Mehdi H Shishehbor; Deepak L Bhatt
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

Review 3.  Therapeutic strategies to deplete macrophages in atherosclerotic plaques.

Authors:  Inge De Meyer; Wim Martinet; Guido R Y De Meyer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

4.  Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals.

Authors:  Rong Yang; Gabrielle Fredman; Sriram Krishnamoorthy; Nitin Agrawal; Daniel Irimia; Daniele Piomelli; Charles N Serhan
Journal:  J Biol Chem       Date:  2011-07-12       Impact factor: 5.157

5.  Circulating platelet and neutrophil activation correlates with the clinical course of unstable angina.

Authors:  Satoshi Murasaki; Kagari Murasaki; Kenjiro Tanoue; Masatoshi Kawana; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2007-11-26       Impact factor: 2.037

Review 6.  Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum.

Authors:  Adriana Vieira-de-Abreu; Robert A Campbell; Andrew S Weyrich; Guy A Zimmerman
Journal:  Semin Immunopathol       Date:  2011-08-06       Impact factor: 9.623

Review 7.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

8.  Detection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1.

Authors:  Meera V Singh; Donna C Davidson; Michelle Kiebala; Sanjay B Maggirwar
Journal:  J Virol Methods       Date:  2012-02-23       Impact factor: 2.014

Review 9.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

10.  Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study.

Authors:  Joanna J Wykrzykowska; Ascan Warnholtz; Peter de Jaeger; Nick Curzen; Keith G Oldroyd; Jean Philippe Collet; Jurrien M Ten Berg; Tessa Rademaker; Dick Goedhart; Jurgen Lissens; Peter-Paul Kint; Patrick W Serruys
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.